NATIONAL TUBERCULOSIS PREVALENCE SURVEY 2016

Similar documents
SURVEY FINDINGS April 28, 2017

Background paper number 7

The 1 st National TB Prevalence Survey Nigeria 2012

The first National TB Prevalence Survey Rwanda 2012

TB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017

The National TB Prevalence Survey Pakistan

Protocol of National TB Prevalence Survey in Cambodia

Outline. Milestone of survey in Myanmar Objectives Method Results Discussion Limitation Programme implications

Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work

National TB Prevalence survey in Myanmar. By Dr. Thandar Lwin Programme Manager National TB Programme Department of Health

TB Disease Prevalence Survey - Overview and Introduction of the TF

Democratic People s Republic of Korea

TB Contact Investigation

TB Disease Prevalence Survey - Progress Report

TB Disease Prevalence Survey - Overview, why and how

Profile of Tuberculosis Infection among Current HIV+ Patients at the Philippine General Hospital

Xpert MTB/RIF assay validation experience --- impact and plan in China

INDEX CASE INFORMATION

The diagnosis of active TB

Report Second National Tuberculosis Prevalence Survey

Dr Richard Christopher,(Pediatrician) Ministry of Health and Social Welfare NTLP- TANZANIA Tanzania. Childhood TB Roadmap Paris 0ctober 29

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Clinical Practice Guideline

Diagnosis and Medical Management of Latent TB Infection

Prevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials

National tuberculosis prevalence surveys in Asia, : an overview of results and lessons learned

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB

Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

Report of WS on Prevalence Survey in Beijing. Norio Yamada RIT/JATA

Ethiopia. Targeted Tuberculosis Case Finding Interventions in Six Mining Shafts in Remote Districts of Oromia Region in Ethiopia PROJECT CONTEXT

Community-Based Surveillance for Drug Resistance of Mycobacterium tuberculosis in Selected Areas in the Philippines

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD

Diagnosis and Treatment of Tuberculosis, 2011

Ministry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)

The analysis of tuberculosis prevalence surveys. Babis Sismanidis with acknowledgements to Sian Floyd Harare, 30 November 2010

Paediatric TB: disease burden estimation and the opportunities it creates to strengthening surveillance

Qian Gao Fudan University

TB control. Assumptions. Reality. Symptomatic patients seek care. Patients and professionals don t recognise symptoms

Ken Jost, BA, has the following disclosures to make:

Ongoing Research on LTBI and Research priorities in India

Diagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre

Comparative performance of emerging rapid diagnostics in HIV-infected individuals

Cities Combating Tuberculosis (CCTB)

Algorithmic Approaches to Child TB Management in Resource-limited Settings

Analysis of TB prevalence surveys

Dr Francis Ogaro MTRH ELDORET

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Northwestern Polytechnic University

Diagnosis of tuberculosis in children

Tuberculosis (TB) and Infection Control PICNET Conference April 12, 2013

Using Xpert to discontinue airborne isolation The Consensus Statement

The need for new TB diagnostics in children and the way forward

Time to Sputum Culture Conversion, identifying independent modifiable risk factors

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Tuberculosis Procedure ICPr016. Table of Contents

Tuberculosis Tools: A Clinical Update

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

World Journal of Pharmaceutical and Life Sciences WJPLS

The Western Pacific Region faces significant

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit

Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis

Ram Sharan Gopali (MPH) Executive Director

TB the basics. (Dr) Margaret (DHA) and John (INZ)

Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining

Urinary TB diagnostics in HIV

GENEXPERT: TOWARDS STANDARD EVALUATION OF A TB INDEX TEST IN CHILDREN

TB infection control: overview and importance

TUBERCULOSIS. Pathogenesis and Transmission

Tuberculosis Epidemiology and Prospects for Control

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

NATIONAL TUBERCULOSIS CONTROL PROGRAM

Prevalence Survey -Global Overview- Background, Survey results since 2007, Lessons and Implications to the program Ikushi Onozaki MD MPH WHO HQ STB

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

Multidrug-Resistant TB

International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007

The Lancet Infectious Diseases

Utilizing All the Tools in the TB Toolbox

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Modeling the diagnosis of HIVassociated

UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME

National Xpert MTB/RIF Programme

INTEGRATION OF PREVENTION AND CONTROL OF NONCOMMUNICABLE DISEASES AND TUBERCULOSIS: A CASE FOR ACTION

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

IMPACT Who We Are Our Strategic Approaches Highlights of Progress Plans for Remaining 6 Months of 2014

New Standards for an Old Disease:

Subgroup Report Prevalence Survey. Ikushi Onozaki WHO/HQ/HTM/STB/TBS

TOG The Way Forward

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Finding the missing TB cases

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

2017/2018 Annual Volunteer Tuberculosis Notice

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.

TB Prevalence Survey. -Census, Interview and X ray- Ikushi Onozaki MD, MPH STB, WHO Geneva

Transcription:

NATIONAL TUBERCULOSIS PREVALENCE SURVEY 2016 Department of Health/National TB Control Program Philippine Council for Health Research and Development Foundation for the Advancement of Clinical Epidemiology, Inc. 2016 NTPS Results 24 th Annual PhilCAT Convention August 17, 2017

To gain a much better understanding of the burden and trend of disease caused by TB. To identify ways in which TB control and care can be improved In order to ensure that TB is no longer a public health threat.

Primary objectives 1) To determine the prevalence of pulmonary TB (PTB) among the population in the Philippines aged 15 years or older for the period 2016, specifically: AFB smear-positive PTB Xpert MTB/RIF-positive PTB Bacteriologically confirmed PTB (Xpert MTB/RIF and/or culture) 2) To assess the trend in TB prevalence with smear-positive PTB and bacteriologically-confirmed TB, compared with the results of the 2007 survey; 3) To contribute to baseline data for related Sustainable Development Goals and End TB Strategy targets.

National TB Prevalence Surveys, Philippines 1983 prevalence Sm +: 6.6/1000 Cult +: 8.6/1000 1997 prevalence Sm +: 3.1/1000 Cult +: 8.1/1000 2007 prevalence Sm +: 2.0/1000 Cult +: 4.7/1000

National TB Prevalence Surveys, Philippines 1983 Sm +: 6.6/1000 Cult +: 8.6/1000 1997 Sm +: 3.1/1000 Cult +: 8.1/1000 Sm +: 2.0/1000 Cult +: 4.7/1000 2007 2016

Overview of Methods

Sampling Multi-stage cluster sampling * 106 out of 108 clusters * 3 replacements in Mindanao within the same province ~ 500 eligible participants per cluster (barangay or purok) Region Number of clusters Region NCR / Region III, IVA 40 Luzon 20 Visayas 21 Mindanao 25

PREPARATIONS & PILOT PHASE: Mid-Oct 2015 mid- March 2016 FIELD SURVEY & LAB WORK: Mid-March 2016 to December 2016 LAB WORK & DATA ANALYSIS: January to July 2017

Survey-eligible population 15 years old and above Resident of the cluster for at least two weeks

Procedures Pre-survey visits and dissemination of info Census of clusters Informed consent Individual interview Digital chest x-ray Sputum collection (if eligible) Post-survey advice and treatment (as needed)

New features of the 2016 NTPS SCREENING: 2 weeks cough and/or Symptom screening AND/OR Digital chest X-ray Hemoptysis SPUTUM COLLECTION

New features of the 2016 NTPS DIAGNOSTIC TESTS: 1 3 SPUTUM specimens Smear microscopy by LED-FM Xpert MTB/RIF Solid culture for mycobacteria

2016 NTPS Findings

Survey protocol vs. survey accomplishments 106 46,689 108 clusters 51,000 sample size SURVEY PROTOCOL 85% participation 15% sputumeligible 76% 39.8%

Outcome of screening process Total Survey Participants 46,689 100%

Outcome of screening process Positively-screened 18,597 40% Negative screening 28,092 60%

Outcome of screening process Symptoms only 1,457 3% Chest x-ray and symptoms 1,358 3% Chest x-ray not done 5,080 11% Chest x-ray only 10,702 23% Negative screening 28,092 60%

Bacteriologically-positive results (N=466) 238 69 159 Xpert MTB/RIF Culture MTB

27/M, cough < 2 weeks, smoker, no DM, no previous TB treatment Xpert low MTB detected, no rif resistance Negative smear Negative culture 58/M, cough < 2 weeks, smoker, no DM, no previous treatment Xpert medium MTB detected, no rif res +1 smear +MTB culture

76/F, cough 2 weeks, non-smoker, weight loss, fever, no DM, previous TB treatment (1965) CXR (3 readings): suspicious for TB, apices; L lower lung field pneumonic infiltrates or pleural effusion/thickening Labs: DSSM, Xpert MTB/RIF, culture NEGATIVE 70/F, cough 2 weeks, weight loss, fever, nonsmoker, no DM, no previous TB treatment CXR (3 readings): suspicious for TB (fibrohazy or reticular), R apex Labs: DSSM, Xpert MTB/RIF, culture NEGATIVE

Overall prevalence of bacteriologically confirmed PTB: 1,159 per 100,000 (95% CI: 1,016 1,301) Overall prevalence of smear-positive PTB: 434 per 100,000 (95% CI: 350 518)

PTB prevalence by Xpert MTB/RIF: 983 per 100,000 (95% CI: 856 1,110) PTB prevalence by MTB culture: 587 per 100,000 (95% CI: 448 687)

Prevalence by sex 1713 per 100,000 (95%CI 1482-1943) 627 per 100,000 (95%CI 516-739)

Prevalence by strata Strata 2: 1038 (787-1288) Strata 1: 1358 (1103-1612) Strata 3: 1234 (873-1594) Strata 4: 856 (686-1026)

Prevalence to notification ratios for bacteriologically confirmed smear-positive PTB cases

TB prevalence in the 3 rd & 4 th NTPS

Category Bacteriologically confirmed TB No. of cases as per protocol* 2007 survey 2016 survey No. of cases as per amended analysis No. of cases as per protocol No. of cases as per amended analysis 136 81 466 212 Culture-positive MTB - 81 (72**) 228 212 Smear-positive MTB 50 36 (33**) 173 118 Amended analysis restricted to the following criteria: Eligibility to participate criteria 2007 survey: 15yrs (N=19,341) 2016 survey: 15yrs and residency status (N=61,467) Participation defined by: 2007 survey: Had a CXR (N=17,226) 2016 survey: Had an interview +/- CXR (N=46,689) Screening outcomes defined by chest X-ray result only i.e. symptom screening excluded TB cases are defined by Ogawa culture result only i.e. LJ excluded. In the 2007 survey, the second sputum specimen result was used and where it was missing or contaminated, the first specimen result was used instead. * Source: final survey report. Smear-positive TB cases only includes those with a positive TB culture (i.e. 5 probable cases were excluded). ** Some IDs from the 2007 laboratory database could not completely merge/match with the main database, and some cases were also excluded because the participant was not eligible to submit samples based on CXR screening (i.e. submitted but not eligible to do so).

Adjusted prevalence estimates for 2007 and 2016: No evidence of decline 2007 2016 Culture-positive TB cases 463 per 100,000 95%CI 333-592 Smear-positive with culture-positive TB 193 per 100,000 95%CI 117-269 512 per 100,000 95%CI 420-603 286 per 100,000 95%CI 223-349 15yrs age group Screening by chest X-ray only Bacteriologically confirmed TB cases are defined by Ogawa culture only Analysis: multiple imputation + inverse probability weighting (20 cycles) 2007 survey variables: age, sex, age_sex_interaction, strata, chronic cough, coughing blood, central CXR result, past treatment of TB 2016 survey variables: age, sex, strata, chronic cough, coughing blood, fever, weight loss, night sweats, field CXR result, central CXR result, past treatment of TB, current treatment of TB, currently smoking tobacco.

Factors associated with TB

Significant risk factors Adjusted odds ratios (95% CI) 1.6 (1.2, 2.0) 1.7 (1.1,2.6) 1.6 (1.1, 2.6) 1.8 (1.4, 2.3) 2.2 (1.6, 3.2) 2.2 (1.5, 3.4) 1.9 (1.3, 2.7) 2.3 (1.7, 3.1) 2.3 (1.6, 3.3) 2.8 (1.8, 4.4) 3.3 (2.7, 4.1) 3.5 (1.9, 6.3) Age Urban dwelling Previous TB treatment Self-reported diabetes mellitus Lower socioeconomic status No health insurance Sex and smoking

Health-seeking behavior: Aug. 18, 2017 PhilCAT lunch symposium

Short-term recommendations Do systematic screening for TB among high-risk and vulnerable groups. The tools to find the missing TB cases must be sharpened and enhanced. Develop innovative behavioral interventions and enablers to improve health care-seeking and adherence to treatment. Reinvigorate and transform PPM partnerships. Strengthen the collaboration between the NTP and other health programs.

Long-term recommendations Develop adequate social protection strategies and PhilHealth TB benefit packages. Vigorous advocacy to increase investments local, national, and international investments to address the TB burden, including quality patient-centered and community-based strategies and health systems strengthening. More comprehensive and sustained poverty alleviation efforts and multi-sectoral partnerships at the local and national levels.

A multi-agency effort: DOH/NTP and NTP partners PCHRD Technical assistance from WHO

Multi-agency effort (2) Implementers: Foundation for the Advancement of Clinical Epidemiology, Inc. Foundation for the Control of Infectious Diseases, Inc. Philippine College of Radiology Network of TB laboratories: National TB Reference Laboratory, Alabang Cebu TB Reference Laboratory Davao TB Reference Laboratory Northern TB Reference Laboratory Region 2 TB Reference Laboratory TB Medical Research Laboratory, Philippine General Hospital In cooperation with the University of the Philippines Manila

With the cooperation of regional, provincial, & local officials, health staff, local volunteers, communities

Thank you!

National TB Prevalence Surveys, Philippines 1983 Sm +: 6.6/1000 Cult +: 8.6/1000 1997 Sm +: 3.1/1000 Cult +: 8.1/1000 2007 Sm +: 2.0/1000 Cult +: 4.7/1000 2016 Sm +: 2.9/1000 Cult +: 5.1/1000 DSSM, Xpert MTB/RIF + culture 2016 Sm +: 4.3/1000 Xpert/cult +: 10.6/1000